In this episode of The Psychedelic Report, Dr. Dave Rabin MD, PhD offers timely commentary on a major recent development in U.S. drug policy: the federal directive to expedite the rescheduling of cannabis from DEA Schedule I to Schedule III. While not yet legalized, this critically important move marks an important acknowledgment of the high degree of safety and medical utility of cannabis and, once rescheduled, will reduce barriers to research, clinical use, and patient access. Dr. Dave breaks down what this shift means, what happens next, and why it may signal a broader turning point for plant medicine and psychedelic research.The White House Announcement concerning Cannabis on Dec 18, 2025 Notes for DOT-employees Web: https://thepsychdedelic.reportInstagram: https://www.instagram.com/drdavidrabinTwitter: https://twitter.com/DrDavidRabin More from Dr. Dave: https://www.drdave.io/ Evidence-Based Guidelines for Treatment of Chronic Pain and Opioid Use Disorders Using Cannabinoids Learn more about your ad choices. Visit megaphone.fm/adchoices